Perosphere (Research Partner)Daiichi Sankyo (Research Partner)
Daiichi Sankyo will support and co-sponsor Phase III trials evaluating Perosphere's PER977 to reverse the anticoagulant activity of Daiichi Sankyo's edoxaban
Daiichi Sankyo (Other)Portola (Other)
Daiichi partnered with Portola to conduct Phase III trials to evaluate the ability of Portola's andexanet alfa (PRT4445) to reverse the anticoagulation activity of Daiichi's edoxaban.
Set Email Alert